0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV127.27%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma17.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Chimerix Stock Discussion
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix (NASDAQ: CMRX) announced updated Phase 2 response assessment results for dordaviprone in treating recurrent H3 K27M-mutant diffuse midline glioma. Using the new RANO 2.0 criteria, the treatment showed a 28.0% overall response rate, with a median time to response of 4.6 months and a median duration of response of 10.4 months. The company plans...
$Tonix Pharmaceuticals (TNXP.US)$
Investors are buying up shares of vaccine producers, antiviral drug makers, and protective equipment companies, hoping to profit as they did during the coronavirus pandemic.
Bavarian Nordic, the only producer approved of the pox vaccine, saw its shares jump 16.5% on the day in...
📊⚡️📊
Phase I dose escalation trials continue at the National Institutes of Health (NIH) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC) in adult and pediatric CNS tumor patients, respectively. The dose escalation trials are currently dosing at a...
No comment yet